Tacrolimus in the treatment of idiopathic nephrotic syndrome

Bibliography

• MEYRIER A: Minimal change and focal-segmental glomerular sclerosis. Oxford Textbook of Clin. Nephrol. (3rd edition). Cameron S, Grunfeld JP, Ponticelli C, Von Ypersele C, Ritz E (Eds), Davison AMA, Oxford, UK (2005).
   Google Scholar
• HAAS M, MEEHAN SM, KARRISON TG, SPARGO BH: Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am. J. Kidney Dis. (1997) 30(5):621-631.
   PubMed Web of Science ®Google Scholar
• KORBET SM, SCHWARTZ MM, LEWIS EJ: Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am. J. Kidney Dis. (1994) 23(6):773-783.
   PubMed Web of Science ®Google Scholar
• CATTRAN DC, APPEL GB, HEBERT LA et al.: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. (1999) 56(6):2220-2226.
   PubMed Web of Science ®Google Scholar
• NOLASCO F, CAMERON JS, HEYWOOD EF, HICKS J, OGG C, WILLIAMS DG: Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int. (1986) 29(6):1215-1223.
   PubMed Web of Science ®Google Scholar
• FUJIMOTO S, YAMAMOTO Y, HISANAGA S, MORITA S, ETO T, TANAKA K: Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse. Am. J. Kidney Dis. (1991) 17(6):687-692.
   PubMed Web of Science ®Google Scholar
• RYDEL JJ, KORBET SM, BOROK RZ, SCHWARTZ MM: Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am. J. Kidney Dis. (1995) 25(4):534-542.
   PubMed Web of Science ®Google Scholar
• CHUN MJ, KORBET SM, SCHWARTZ MM, LEWIS EJ: Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J. Am. Soc. Nephrol. (2004) 15(8):2169-2177.
   PubMed Web of Science ®Google Scholar
• CATTRAN DC, DELMORE T, ROSCOE J et al.: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N. Engl. J. Med. (1989) 320(4):210-215.
   PubMed Web of Science ®Google Scholar
• CAMERON JS, HEALY MJ, ADU D: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. QJ Med. (1990) 74(274):133-156.
   PubMedGoogle Scholar
• BRAUN MC, WEST CD, STRIFE CF: Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Am. J. Kidney Dis. (1999) 34(6):1022-1032.
   PubMed Web of Science ®Google Scholar
• BERNS JS, GAUDIO KM, KRASSNER LS et al.: Steroid-responsive nephrotic syndrome of childhood: a long-term study of clinical course, histopathology, efficacy of cyclophosphamide therapy, and effects on growth. Am. J. Kidney Dis. (1987) 9(2):108-114.
   PubMed Web of Science ®Google Scholar
• SCHULMAN SL, KAISER BA, POLINSKY MS, SRINIVASAN R, BALUARTE HJ: Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J. Pediatr. (1988) 113(6):996-1001.
   PubMed Web of Science ®Google Scholar
• KALDOR JM, DAY NE, PETTERSSON F et al.: Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med. (1990) 322(1):1-6.
   PubMed Web of Science ®Google Scholar
• ABRAMOWICZ M, BARNETT HL, EDELMANN CM Jr et al.: Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children. Lancet (1970) 1(7654):959-961.
   PubMed Web of Science ®Google Scholar
• BRIGGS WA, CHOI MJ, SCHEEL PJ Jr: Successful mycophenolate mofetil treatment of glomerular disease. Am. J. Kidney Dis. (1998) 31(2):213-217.
   PubMed Web of Science ®Google Scholar
• CHOI MJ, EUSTACE JA, GIMENEZ LF et al.: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. (2002) 61(3):1098-114.
   PubMed Web of Science ®Google Scholar
• DAY CJ, COCKWELL P, LIPKIN GW, SAVAGE CO, HOWIE AJ, ADU D: Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol. Dial. Transplant. (2002) 17(11):2011-2013.
   PubMed Web of Science ®Google Scholar
• MELOCOTON TL, KAMIL ES, COHEN AH, FINE RN: Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am. J. Kidney Dis. (1991) 18(5):583-588.
   PubMed Web of Science ®Google Scholar
• MEYRIER A, NOEL LH, AURICHE P, CALLARD P: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int. (1994) 45(5):1446-1456.
   PubMed Web of Science ®Google Scholar
• TEJANI AT, BUTT K, TRACHTMAN H, SUTHANTHIRAN M, ROSENTHAL CJ, KHAWAR MR: Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int. (1988) 33(3):729-734.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, EDEFONTI A, GHIO L et al.: Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol. Dial. Transplant. (1993) 8(12):1326-1332.
   PubMed Web of Science ®Google Scholar
• NIAUDET P: Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr. Nephrol. (1992) 6(1):1-3.
   PubMed Web of Science ®Google Scholar
• MEYRIER A: Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol. Dial. Transplant. (2003) 18(Suppl. 6):vi79-vi86.
   PubMedGoogle Scholar
• CATTRAN DC, RAO P: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am. J. Kidney Dis. (1998) 32(1):72-79.
   PubMed Web of Science ®Google Scholar
• BANFI G, MORIGGI M, SABADINI E, FELLIN G, D’AMICO G, PONTICELLI C: The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin. Nephrol. (1991) 36(2):53-59.
   PubMed Web of Science ®Google Scholar
• HEERING P, BRAUN N, MULLEJANS R et al.: Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am. J. Kidney Dis. (2004) 43(1):10-18.
   PubMed Web of Science ®Google Scholar
• MONTANE B, ABITBOL C, CHANDAR J, STRAUSS J, ZILLERUELO G: Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr. Nephrol. (2003) 18(8):772-777.
   PubMed Web of Science ®Google Scholar
• LIEBERMAN KV, TEJANI A: A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J. Am. Soc. Nephrol. (1996) 7(1):56-63.
   PubMed Web of Science ®Google Scholar
• NIAUDET P: Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Paediatric Nephrology. J. Pediatr. (1994) 125(6 Part 1):981-986.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, RIZZONI G, EDEFONTI A et al.: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. (1993) 43(6):1377-1384.
   PubMed Web of Science ®Google Scholar
• TUMLIN JA, MILLER D, NEAR M, SELVARAJ S, HENNIGAR R, GUASCH A: A Prospective, Open-Label Trial of Sirolimus in the Treatment of Focal Segmental Glomerulosclerosis. Clin. J. Am. Soc. Nephrol. (2006) 1:109-116.
   PubMed Web of Science ®Google Scholar
• FERVENZA FC, FITZPATRICK PM, MERTZ J et al.: Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol. Dial. Transplant. (2004) 19(5):1288-1292.
   PubMed Web of Science ®Google Scholar
• CHO ME, HURLEY JK, KOPP JB: Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am. J. Kidney Dis. (2007) 49(2):310-317.
   PubMed Web of Science ®Google Scholar
• DU BUF-VEREIJKEN PW, BRANTEN AJ, WETZELS JF: Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am. J. Kidney Dis. (2005) 46(6):1012-1029.
   PubMed Web of Science ®Google Scholar
• HOGAN SL, MULLER KE, JENNETTE JC, FALK RJ: A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney Dis. (1995) 25(6):862-875.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, ZUCCHELLI P, PASSERINI P et al.: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. (1995) 48(5):1600-1604.
   PubMed Web of Science ®Google Scholar
• JINDAL K, WEST M, BEAR R, GOLDSTEIN M: Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am. J. Kidney Dis. (1992) 19(1):61-67.
   PubMed Web of Science ®Google Scholar
• PONTICELLI C, ZUCCHELLI P, PASSERINI P, CESANA B: Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N. Engl. J. Med. (1992) 327(9):599-603.
   PubMed Web of Science ®Google Scholar
• CATTRAN DC, APPEL GB, HEBERT LA et al.: Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. (2001) 59(4):1484-1490.
   PubMed Web of Science ®Google Scholar
• MUIRHEAD N: Management of idiopathic membranous nephropathy: evidence-based recommendations. Kidney Int. Suppl. (1999) 70:S47-S55.
   PubMedGoogle Scholar
• MILLER G, ZIMMERMAN RR, RADHAKRISHNAN J, APPEL G: Use of mycophenolate mofetil in resistant membranous nephropathy. Am. J. Kidney Dis. (2000) 36(2):250-256.
   PubMed Web of Science ®Google Scholar
• GOUMENOS DS, AHUJA M, DAVLOUROS P, EL NAHAS AM, BROWN CB: Prednisolone and azathioprine in membranous nephropathy: a 10-year follow-up study. Clin. Nephrol. (2006) 65(5):317-323.
   PubMed Web of Science ®Google Scholar
• AHUJA M, GOUMENOS D, SHORTLAND JR, GERAKIS A, BROWN CB: Does immunosuppression with prednisolone and azathioprine alter the progression of idiopathic membranous nephropathy? Am. J. Kidney Dis. (1999) 34(3):521-529.
   PubMed Web of Science ®Google Scholar
• DONADIO JV Jr, ANDERSON CF, MITCHELL JC IIIet al.: Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N. Engl. J. Med. (1984) 310(22):1421-1426.
   PubMed Web of Science ®Google Scholar
• KINO T, HATANAKA H, MIYATA S et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo) (1987) 40(9):1256-1265.
   PubMed Web of Science ®Google Scholar
• KINO T, HATANAKA H, HASHIMOTO M et al.: FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. (Tokyo) (1987) 40(9):1249-1255.
   PubMed Web of Science ®Google Scholar
• OCHIAI T, NAKAJIMA K, NAGATA M et al.: Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant. Proc. (1987) 19(1 Part 2):1284-1286.
   PubMed Web of Science ®Google Scholar
• ELLIS D: Clinical use of tacrolimus (FK-506) in infants and children with renal transplants. Pediatr. Nephrol. (1995) 9(4):487-494.
   PubMed Web of Science ®Google Scholar
• LASKOW DA, NEYLAN JF III, SHAPIRO RS, PIRSCH JD, VERGNE-MARINI PJ, TOMLANOVICH SJ: The role of tacrolimus in adult kidney transplantation: a review. Clin. Transplant. (1998) 12(6):489-503.
   PubMed Web of Science ®Google Scholar
• TEPEL M, BACHMANN J, SCHLUTER H, ZIDEK W: Diadenosine polyphosphates increase cytosolic calcium and attenuate angiotensin-II-induced changes of calcium in vascular smooth muscle cells. J. Vasc. Res. (1996) 33(2):132-138.
   PubMed Web of Science ®Google Scholar
• BRAM RJ, HUNG DT, MARTIN PK, SCHREIBER SL, CRABTREE GR: Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol. Cell. Biol. (1993) 13(8):4760-4769.
   PubMed Web of Science ®Google Scholar
• SCHREIBER SL, LIU J, ALBERS MW et al.: Immunophilin-ligand complexes as probes of intracellular signaling pathways. Transplant. Proc. (1991) 23(6):2839-2844.
   PubMed Web of Science ®Google Scholar
• SIEKIERKA JJ, HUNG SH, POE M, LIN CS, SIGAL NH: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 341(6244):755-757.
   PubMed Web of Science ®Google Scholar
• KAPTURCZAK MH, MEIER-KRIESCHE HU, KAPLAN B: Pharmacology of calcineurin antagonists. Transplant. Proc. (2004) 36(Suppl. 2):25S-32S.
   PubMed Web of Science ®Google Scholar
• FRANTZ B, NORDBY EC, BREN G et al.: Calcineurin acts in synergy with PMA to inactivate I κ B/MAD3, an inhibitor of NF-κB. EMBO J. (1994) 13(4):861-870.
   PubMed Web of Science ®Google Scholar
• APERIA A, IBARRA F, SVENSSON LB, KLEE C, GREENGARD P: Calcineurin mediates α-adrenergic stimulation of Na+,K+-ATPase activity in renal tubule cells. Proc. Natl. Acad. Sci. USA (1992) 89(16):7394-7397.
   PubMed Web of Science ®Google Scholar
• DAWSON TM, STEINER JP, DAWSON VL, DINERMAN JL, UHL GR, SNYDER SH: Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc. Natl. Acad. Sci. USA (1993) 90(21):9808-9812.
   PubMed Web of Science ®Google Scholar
• SAWADA S, SUZUKI G, KAWASE Y, TAKAKU F: Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. (1987) 139(6):1797-803.
   PubMed Web of Science ®Google Scholar
• DUMONT FJ, STARUCH MJ, KOPRAK SL, MELINO MR, SIGAL NH: Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. (1990) 144(1):251-258.
   PubMed Web of Science ®Google Scholar
• LIN CS, BOLTZ RC, SIEKIERKA JJ, SIGAL NH: FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell. Immunol. (1991) 133(2):269-284.
   PubMed Web of Science ®Google Scholar
• TOCCI MJ, MATKOVICH DA, COLLIER KA et al.: The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. (1989) 143(2):718-726.
   PubMed Web of Science ®Google Scholar
• MOHAMED MA, ROBERTSON H, BOOTH TA, BALUPURI S, KIRBY JA, TALBOT D: TGF-β expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. Transplantation (2000) 69(5):1002-1005.
   PubMed Web of Science ®Google Scholar
• VENKATARAMANAN R, JAIN A, WARTY VS et al.: Pharmacokinetics of FK 506 in transplant patients. Transplant. Proc. (1991) 23(6):2736-2740.
   PubMed Web of Science ®Google Scholar
• WALLEMACQ PE, VERBEECK RK: Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin. Pharmacokinet. (2001) 40(4):283-295.
   PubMed Web of Science ®Google Scholar
• NEYLAN JF: Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation (1998) 65(4):515-523.
   PubMed Web of Science ®Google Scholar
• NEYLAN JF: Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant. Proc. (1998) 30(4):1355-1358.
   PubMed Web of Science ®Google Scholar
• JAIN AB, VENKATARAMANAN R, CADOFF Eet al.: Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant. Proc. (1990) 22(1):57-59.
   PubMed Web of Science ®Google Scholar
• JUSKO WJ, D’AMBROSIO R: Monitoring FK 506 concentrations in plasma and whole blood. Transplant. Proc. (1991) 23(6):2732-2735.
   PubMed Web of Science ®Google Scholar
• KAY JE, SAMPARE-KWATENG E, GERAGHTY F, MORGAN GY: Uptake of FK 506 by lymphocytes and erythrocytes. Transplant. Proc. (1991) 23(6):2760-2762.
   PubMed Web of Science ®Google Scholar
• KELLY P, KAHAN BD: Review: metabolism of immunosuppressant drugs. Curr. Drug Metab. (2002) 3(3):275-287.
   PubMed Web of Science ®Google Scholar
• JAIN AB, FUNG JJ, TZAKIS AG et al.: Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant. Proc. (1991) 23(6):2763-2766.
   PubMed Web of Science ®Google Scholar
• MCCAULEY J, TZAKIS AG, FUNG JJ, TODO S, STARZL TE: FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 335(8690):674.
   PubMedGoogle Scholar
• PENNESI M, GAGLIARDO A, MINISINI S: Effective tacrolimus treatment in a child suffering from severe nephrotic syndrome. Pediatr. Nephrol. (2003) 18(5):477-478.
   PubMed Web of Science ®Google Scholar
• TSUGAWA K, TANAKA H, NAKAHATA T, ITO E: Effective therapy of a child case of refractory nephrotic syndrome with tacrolimus. Tohoku J. Exp. Med. (2004) 204(3):237-241.
   PubMed Web of Science ®Google Scholar
• BHATIA M, KHER K, MINNITI CP: Acute lymphoblastic leukemia in a child with nephrotic syndrome. Pediatr. Nephrol. (2004) 19(11):1290-1293.
   PubMed Web of Science ®Google Scholar
• PANDIRIKKAL VB, JAIN M, GULATI S: Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome. Pediatr. Nephrol. (2007) 22(2):298-300.
   PubMed Web of Science ®Google Scholar
• BENZ K, DOTSCH J, RASCHER W, STACHEL D: Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr. Nephrol. (2004) 19(7):794-797.
   PubMed Web of Science ®Google Scholar
• OSUGI Y, YAMADA H, HOSOI Get al.: Treatment with candesartan combined with angiotensin-converting enzyme inhibitor for immunosuppressive treatment-resistant nephrotic syndrome after allogeneic stem cell transplantation. Int. J. Hematol. (2006) 83(5):454-458.
   PubMed Web of Science ®Google Scholar
• DITTRICH K, KNERR I, RASCHER W, DOTSCH J: Transient insulin-dependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment. Pediatr. Nephrol. (2006) 21(7):958-961.
   PubMed Web of Science ®Google Scholar
• LOEFFLER K, GOWRISHANKAR M, YIU V: Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr. Nephrol. (2004) 19(3):281-287.
   PubMed Web of Science ®Google Scholar
• SINHA MD, MACLEOD R, RIGBY E, CLARK AG: Treatment of severe steroid-dependent nephrotic syndrome(SDNS) in children with tacrolimus. Nephrol. Dial. Transplant. (2006) 21(7):1848-1854.
   PubMed Web of Science ®Google Scholar
• SCHWEDA F, LIEBL R, RIEGGER GA, KRAMER BK: Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrol. Dial. Transplant. (1997) 12(11):2433-2435.
   PubMed Web of Science ®Google Scholar
• TANG S, TANG AW, TAM MK, HO YW: Use of tacrolimus in steroid- and cyclophosphamide-resistant minimal change nephrotic syndrome. Am. J. Kidney Dis. (2003) 42(5):E13-E15.
   PubMedGoogle Scholar
• PATEL P, PAL S, ASHLEY C, SWENY P, BURNS A: Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report. Nephrol. Dial. Transplant. (2005) 20(5):985-987.
   PubMed Web of Science ®Google Scholar
• KUHN C, KUHN A, MARKAU S, KASTNER U, OSTEN B: Effect of immunoadsorption on refractory idiopathic focal and segmental glomerulosclerosis. J. Clin. Apher. (2006) 21(4):266-270.
   PubMed Web of Science ®Google Scholar
• CHANDRA M, SUSIN M, ABITBOL C: Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr. Nephrol. (2000) 14(3):224-226.
   PubMed Web of Science ®Google Scholar
• KESSLER M, CHAMPIGNEULLES J, HESTIN D, FRIMAT L, RENOULT E: A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. Transplantation (1999) 67(4):641-643.
   PubMed Web of Science ®Google Scholar
• MCCAULEY J, SHAPIRO R, ELLIS D, IGDAL H, TZAKIS A, STARZL TE: Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol. Dial. Transplant. (1993) 8(11):1286-1290.
   PubMed Web of Science ®Google Scholar
• SEGARRA A, VILA J, POU Let al.: Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol. Dial. Transplant. (2002) 17(4):655-662.
   PubMed Web of Science ®Google Scholar
• DUNCAN N, DHAYGUDE A, OWEN Jet al.: Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol. Dial. Transplant. (2004) 19(12):3062-3067.
   PubMed Web of Science ®Google Scholar
• WESTHOFF TH, SCHMIDT S, ZIDEK W, BEIGE J, VAN DER GIET M: Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin. Nephrol. (2006) 65(6):393-400.
   PubMed Web of Science ®Google Scholar
• MIAO L, SUN J, YUAN H, JIA Y, XU Z: Combined therapy of low-dose tacrolimus and prednisone in nephrotic syndrome with slight mesangial proliferation. Nephrology (Carlton) (2006) 11(5):449-454.
   PubMed Web of Science ®Google Scholar
• XIA Z, LIU G, GAO Yet al.: FK506 in the treatment of children with nephrotic syndrome of different pathological types. Clin. Nephrol. (2006) 66(2):85-88.
   PubMed Web of Science ®Google Scholar
• BHIMMA R, ADHIKARI M, ASHARAM K, CONNOLLY C: Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am. J. Nephrol. (2006) 26(6):544-551.
   PubMed Web of Science ®Google Scholar
• VAN HOOFF JP, CHRISTIAANS MH, VAN DUIJNHOVEN EM: Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation (2005) 79(11):1465-1469.
   PubMed Web of Science ®Google Scholar
• OFFERMANN G: Immunosuppression for long-term maintenance of renal allograft function. Drugs (2004) 64(12):1325-1338.
   PubMed Web of Science ®Google Scholar
• STEELE JA, CHOI C, KWONG PC: Topical tacrolimus in the treatment of inverse psoriasis in children. J. Am. Acad. Dermatol. (2005) 53(4):713-716.
   PubMed Web of Science ®Google Scholar
• AMBALAVANAN S, FAUVEL JP, SIBLEY RK, MYERS BD: Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J. Am. Soc. Nephrol. (1996) 7(2):290-298.
   PubMed Web of Science ®Google Scholar
• CHEN D, JEFFERSON B, HARVEY SJet al.: Cyclosporine a slows the progressive renal disease of alport syndrome(X-linked hereditary nephritis): results from a canine model. J. Am. Soc. Nephrol. (2003) 14(3):690-698.
   PubMed Web of Science ®Google Scholar